United States-based Signant Health has added Anthony Todd Everhart, MD, FACP to the Signant Health Science and Medicine Team as clinical vice president, Internal Medicine, it was reported yesterday.
Dr Everhart is to report to the chief medical officer, Dr David Daniel. He is a board-certified in Internal Medicine and a fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development. Prior to joining Signant, Dr Everhart held positions of vice president, Medical Affairs and vice president, Medical Informatics at Chiltern and Covance, and most recently consulted independently in the areas of Medical Monitoring, Medical Data Review, and Physician Adoption of Technology. He has worked in all phases of clinical development in numerous therapeutic areas including Allergy & Immunology, Cardiovascular, Haematology & Oncology, Infectious Disease & HIV, Neurology, Ophthalmology, Psychiatry, Respiratory, and Rheumatology.
In the new role, Dr Everhart will help accelerate the application of Signant's intelligent eCOA, rater training, predictive analytics and other data quality monitoring products outside of CNS disorders.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib